Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Siebzehnrübl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen HP, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, Petersén Å, von Hörsten S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8765-E8774. doi: 10.1073/pnas.1807962115. Epub 2018 Aug 27.

2.

Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.

Franich NR, Basso M, André EA, Ochaba J, Kumar A, Thein S, Fote G, Kachemov M, Lau AL, Yeung SY, Osmand A, Zeitlin SO, Ratan RR, Thompson LM, Steffan JS.

J Huntingtons Dis. 2018;7(2):137-150. doi: 10.3233/JHD-170274.

3.

Punch graft versus follicular hair transplantation in the treatment of stable vitiligo.

Mohamed Mohamed EE, Younes AK, Osmand A, Mohamed R, Makki M, Younis M.

J Cosmet Laser Ther. 2017 Oct;19(5):290-293. doi: 10.1080/14764172.2017.1303170. Epub 2017 Mar 8.

PMID:
28272910
4.

Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.

Bichell TJV, Wegrzynowicz M, Tipps KG, Bradley EM, Uhouse MA, Bryan M, Horning K, Fisher N, Dudek K, Halbesma T, Umashanker P, Stubbs AD, Holt HK, Kwakye GF, Tidball AM, Colbran RJ, Aschner M, Neely MD, Di Pardo A, Maglione V, Osmand A, Bowman AB.

Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1596-1604. doi: 10.1016/j.bbadis.2017.02.013. Epub 2017 Feb 16.

5.

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease.

Osmand AP, Bichell TJ, Bowman AB, Bates GP.

J Huntingtons Dis. 2016 Dec 15;5(4):343-346.

6.

Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Kratter IH, Zahed H, Lau A, Tsvetkov AS, Daub AC, Weiberth KF, Gu X, Saudou F, Humbert S, Yang XW, Osmand A, Steffan JS, Masliah E, Finkbeiner S.

J Clin Invest. 2016 Sep 1;126(9):3585-97. doi: 10.1172/JCI80339. Epub 2016 Aug 15.

7.

αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.

Oliveira AO, Osmand A, Outeiro TF, Muchowski PJ, Finkbeiner S.

Hum Mol Genet. 2016 May 1;25(9):1677-89. doi: 10.1093/hmg/ddw028. Epub 2016 Feb 26.

8.

IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes.

Becker A, Eichentopf R, Sedlmeier R, Waniek A, Cynis H, Koch B, Stephan A, Bäuscher C, Kohlmann S, Hoffmann T, Kehlen A, Berg S, Freyse EJ, Osmand A, Plank AC, Roßner S, von Hörsten S, Graubner S, Demuth HU, Schilling S.

Biol Chem. 2016 Jan;397(1):45-55. doi: 10.1515/hsz-2015-0192.

PMID:
26351917
9.

Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB.

J Huntingtons Dis. 2015;4(1):17-36.

10.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
11.

Critical role of microRNA-155 in herpes simplex encephalitis.

Bhela S, Mulik S, Reddy PB, Richardson RL, Gimenez F, Rajasagi NK, Veiga-Parga T, Osmand AP, Rouse BT.

J Immunol. 2014 Mar 15;192(6):2734-43. doi: 10.4049/jimmunol.1302326. Epub 2014 Feb 10.

12.

Further molecular characterisation of the OVT73 transgenic sheep model of Huntington's disease identifies cortical aggregates.

Huntington's Disease Sheep Collaborative Research Group, Reid SJ, Patassini S, Handley RR, Rudiger SR, McLaughlan CJ, Osmand A, Jacobsen JC, Morton AJ, Weiss A, Waldvogel HJ, MacDonald ME, Gusella JF, Bawden CS, Faull RL, Snell RG.

J Huntingtons Dis. 2013;2(3):279-95. doi: 10.3233/JHD-130067.

PMID:
25062676
13.

A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.

Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP.

J Neurosci. 2012 Oct 31;32(44):15426-38. doi: 10.1523/JNEUROSCI.1148-12.2012.

14.

Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study.

Tada M, Coon EA, Osmand AP, Kirby PA, Martin W, Wieler M, Shiga A, Shirasaki H, Tada M, Makifuchi T, Yamada M, Kakita A, Nishizawa M, Takahashi H, Paulson HL.

Acta Neuropathol. 2012 Nov;124(5):749-60. doi: 10.1007/s00401-012-1005-5. Epub 2012 Jun 27.

15.

Identifying polyglutamine protein species in situ that best predict neurodegeneration.

Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, Segal M, Yang XW, Masliah E, Thompson LM, Muchowski PJ, Weisgraber KH, Finkbeiner S.

Nat Chem Biol. 2011 Oct 30;7(12):925-34. doi: 10.1038/nchembio.694. Erratum in: Nat Chem Biol. 2012 Mar;8(3):318.

16.

Microstructural changes observed with DKI in a transgenic Huntington rat model: evidence for abnormal neurodevelopment.

Blockx I, De Groof G, Verhoye M, Van Audekerke J, Raber K, Poot D, Sijbers J, Osmand AP, Von Hörsten S, Van der Linden A.

Neuroimage. 2012 Jan 16;59(2):957-67. doi: 10.1016/j.neuroimage.2011.08.062. Epub 2011 Aug 30.

PMID:
21906685
17.

Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.

Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rübsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth HU, von Hörsten S.

J Neurosci. 2011 Sep 7;31(36):12790-801. doi: 10.1523/JNEUROSCI.1794-11.2011.

18.

An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.

Wilburn B, Rudnicki DD, Zhao J, Weitz TM, Cheng Y, Gu X, Greiner E, Park CS, Wang N, Sopher BL, La Spada AR, Osmand A, Margolis RL, Sun YE, Yang XW.

Neuron. 2011 May 12;70(3):427-40. doi: 10.1016/j.neuron.2011.03.021.

19.

Early autophagic response in a novel knock-in model of Huntington disease.

Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ.

Hum Mol Genet. 2010 Oct 1;19(19):3702-20. doi: 10.1093/hmg/ddq285. Epub 2010 Jul 8.

20.

Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP.

J Biol Chem. 2010 Mar 19;285(12):8808-23. doi: 10.1074/jbc.M109.075028. Epub 2010 Jan 19.

21.

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.

Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW.

Neuron. 2009 Dec 24;64(6):828-40. doi: 10.1016/j.neuron.2009.11.020.

22.

Imaging polyglutamine deposits in brain tissue.

Osmand AP, Berthelier V, Wetzel R.

Methods Enzymol. 2006;412:106-22. Review.

PMID:
17046655
23.

Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease.

Nguyen HP, Kobbe P, Rahne H, Wörpel T, Jäger B, Stephan M, Pabst R, Holzmann C, Riess O, Korr H, Kántor O, Petrasch-Parwez E, Wetzel R, Osmand A, von Hörsten S.

Hum Mol Genet. 2006 Nov 1;15(21):3177-94. Epub 2006 Sep 19.

PMID:
16984963
24.

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR.

Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11402-7. Epub 2005 Aug 2.

25.

Expression and distribution of the dentatorubral-pallidoluysian atrophy gene product (atrophin-1/drplap) in neuronal and non-neuronal tissues.

Knight SP, Richardson MM, Osmand AP, Stakkestad A, Potter NT.

J Neurol Sci. 1997 Feb 27;146(1):19-26.

PMID:
9077491
26.

Focal cortical hypermetabolism during transcranial magnetic stimulation.

Meyer M, Osmand A, Campbell S, Logan G.

Muscle Nerve. 1994 Dec;17(12):1464-5. No abstract available.

PMID:
7969248
27.

Cytokine mediation of the suppressive effect of ferritin on colony-stimulating factor-1-dependent monocytopoiesis.

Kreisberg R, Detrick MS, Osmand AP, Moore RN.

J Immunol. 1993 Jun 1;150(11):5094-103.

PMID:
8496605
28.

Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report.

Hof PR, Archin N, Osmand AP, Dougherty JH, Wells C, Bouras C, Morrison JH.

Acta Neuropathol. 1993;86(3):215-23.

PMID:
8213079
29.

Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.

Mester JC, Highlander SL, Osmand AP, Glorioso JC, Rouse BT.

J Virol. 1990 Nov;64(11):5277-83.

30.

Neurotensin regulation of macrophage colony-stimulating factor-stimulated in vitro myelopoiesis.

Moore RN, Osmand AP, Dunn JA, Joshi JG, Koontz JW, Rouse BT.

J Immunol. 1989 Apr 15;142(8):2689-94.

PMID:
2784814
31.

Substance P augmentation of CSF-1-stimulated in vitro myelopoiesis. A two-signal progenitor restricted, tuftsin-like effect.

Moore RN, Osmand AP, Dunn JA, Joshi JG, Rouse BT.

J Immunol. 1988 Oct 15;141(8):2699-703.

PMID:
2459223
32.

Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D.

Wyckoff JH 3rd, Osmand AP, Eisenberg RJ, Cohen GH, Rouse BT.

Immunobiology. 1988 May;177(2):134-48.

PMID:
2456985
33.

Liquid caustic ingestions: an in vitro study of the effects of buffer, neutralization, and dilution.

Maull KI, Osmand AP, Maull CD.

Ann Emerg Med. 1985 Dec;14(12):1160-2.

PMID:
4061986
34.
35.

Interactions of C-reactive protein and complement with liposomes.

Richards RL, Gewurz H, Osmand AP, Alving CR.

Proc Natl Acad Sci U S A. 1977 Dec;74(12):5672-6.

36.

Interactions of C-reactive protein with the first component of human complement.

Claus DR, Siegel J, Petras K, Osmand AP, Gewurz H.

J Immunol. 1977 Jul;119(1):187-92. No abstract available.

PMID:
17637
37.
38.

Inhibition of rabbit platelet aggregation and clot retraction by rabbit and human c-reactive proteins.

Marder RJ, Fiedel BA, Osmand AP, Gewurz H.

Proc Soc Exp Biol Med. 1977 May;155(1):44-7. No abstract available.

PMID:
859881
39.

C-reative protein in the rabbit: isolation, characterization and binding affinity to phosphocholine.

Bach BA, Gewurz H, Osmand AP.

Immunochemistry. 1977 Mar;14(3):215-9. No abstract available.

PMID:
863467
40.
41.

Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins).

Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E.

Proc Natl Acad Sci U S A. 1977 Feb;74(2):739-43.

43.

Inhibition of platelet aggregation by a myeloma protein with anti-phosphocholine specificity.

Fiedel BA, Osmand AP, Gewurz H.

Nature. 1976 Oct 21;263(5579):687-9. No abstract available.

PMID:
62285
44.

IgE myeloma presenting with classical myeloma features.

Weiner E, DiCamelli R, Showel J, Osmand AP, Sassetti RJ, Gewurz H.

J Allergy Clin Immunol. 1976 Sep;58(3):373-80.

PMID:
823190
45.

Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis.

Mortensen RF, Osmand AP, Lint TF, Gewurz H.

J Immunol. 1976 Sep;117(3):774-81.

PMID:
60448
46.

Radioimmunoassay of human C-reactive protein and levels in normal sera.

Claus DR, Osmand AP, Gewurz H.

J Lab Clin Med. 1976 Jan;87(1):120-8.

PMID:
1245780

Supplemental Content

Loading ...
Support Center